DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ovarian dysfunction — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian dysfunction maps to a 36-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian dysfunction is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
centromere protein E (CENPE) — CENPE is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet anpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8HFH · 1.8 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER (ANP). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cochrane Database of Systematic Reviews · 2011 · 3 citations
Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood cancer and cancer in the reproductive age
AbstractThis is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The first objective is to evaluate the incidence of ovarian dysfunction after treatment with chemotherapy for childhood cancer or cancer at the reproductive age. The second objective is to evaluate whether ovarian function is diminished by the following factors: specific chemotherapy group (e.g. alkylating agents, anthracyclins etc.) or specific chemotherapy agent (e.g. cyclophosphamide, daunorubicin etc.), dose of chemotherapy, age at time of treatment, time since treatment and surgery to the hypothalamic‐pituitary‐ovary axis.
Archives of Gynecology and Obstetrics · 2025 · 3 citations · open access
Melatonin: a potential target for regulating ovarian function
AbstractOBJECTIVE: This review explores the important role of melatonin in ovarian function. BACKGROUND: The main manifestations of ovarian dysfunction are a decline in oocyte quality and a reduction in the number of follicles and oocytes. Current evidence suggests that environmental pollution, fungi, mycotoxins, drugs, and lifestyle are risk factors affecting ovarian function. Melatonin (MT) is an endogenous hormone synthesized by pineal gland cells, which has strong endogenous effects on scavenging free radicals and antioxidant damage. Previous studies have shown that melatonin plays a beneficial role in oocyte maturation, fertilization, and embryonic development. It can protect these cells from oxidative damage by clearing excessive free radicals, thereby regulating ovarian function and delaying ovarian aging. CONCLUSIONS: This article reviews and discusses the relationship between melatonin and ovarian function regulation, including the synthesis and secretion of melatonin, the local synthesis and main role of melatonin in the ovaries, and the alleviating effect of melatonin on ovarian function decline caused by different injury factors. SIGNIFICANCE: This review provides important theoretical basis for clinical regulation of ovarian function.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
